Open Access


Read more
image01

Online Manuscript Submission


Read more
image01

Submitted Manuscript Trail


Read more
image01

Online Payment


Read more
image01

Online Subscription


Read more
image01

Email Alert



Read more
image01

Original Research Article | OPEN ACCESS

Arylsulfonyl indoline-enzamide exhibits inhibitory effect on nasopharyngeal carcinoma

Yang Jing1,2, Wen Zhang2, Hui Liu2, Yujuan Wang2, Guoxi Zheng1

1Department of Otorhinolaryngological, The Second Affiliated Hospital of Xi’an Jiaotong University (Xibei Hospital), Xi’an Shaanxi 710004; 2Department of Otorhinolaryngological, Shaanxi Provincial People’s Hospital, Xi’an Shaanxi 710068, China.

For correspondence:-  Guoxi Zheng   Email: GideonMarquezffo@yahoo.com   Tel:+862987679000

Accepted: 22 July 2019        Published: 28 August 2019

Citation: Jing Y, Zhang W, Liu H, Wang Y, Zheng G. Arylsulfonyl indoline-enzamide exhibits inhibitory effect on nasopharyngeal carcinoma. Trop J Pharm Res 2019; 18(8):1643-1649 doi: 10.4314/tjpr.v18i8.11

© 2019 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the effect of arylsulfonyl indoline-benzamide (ASIB) on the viability of nasopharyngeal carcinoma (NPC) cells, and the underlying mechanism of action.
Methods: The viability of C666 and NPC 039 cells was determined using 3-(4, 5-dimethylthiazol-2-yl) 2, 5-diphenyltetrazolium bromide (MTT) assay. Cell migration was analysed by wound healing assay, while protein expression levels of matrix metalloproteinases (MMPs), p50, p65 and NF κB were assayed using western blotting.
Results: MTT assay results showed that ASIB treatment led to significant and dose-dependent reductions in the viability of C666 and NPC 039 (p F6; 0.05). The migration and invasive potential of C666 cells were decreased on incubation with ASIB for 48 h. Western blotting data showed significant decrease in MMP 2/9 expressions in C666 cells on treatment with ASIB (p F6; 0.05). The levels of p65 and p50 in the nuclear fraction of C666 cells were markedly lower than those in the negative control group. Arylsulfonyl indoline-benzamide (ASIB) treatment for 48 h decreased the level of NF κB expression in C666 cells (p F6; 0.05). The volume of tumor excised from ASIB-treated NPC mice was lower than that of the untreated group.
Conclusion: Arylsulfonyl indoline-benzamide (ASIB) exhibits inhibitory effects on the viability and metastasis potential of NPC cells. Thus, it may be beneficial in the treatment of nasopharyngeal carcinoma but this has to be further investigated.

Keywords: Metastasis, extracellular matrix, nuclear fraction, pathogenesis

Impact Factor
Thompson Reuters (ISI): 0.6 (2023)
H-5 index (Google Scholar): 49 (2023)

Article Tools

Share this article with



Article status: Free
Fulltext in PDF
Similar articles in Google
Similar article in this Journal:

Archives

2024; 23: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10
2023; 22: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2022; 21: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2021; 20: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2020; 19: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2019; 18: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2018; 17: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2017; 16: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2016; 15: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2015; 14: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2014; 13: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2013; 12: 
1,   2,   3,   4,   5,   6
2012; 11: 
1,   2,   3,   4,   5,   6
2011; 10: 
1,   2,   3,   4,   5,   6
2010; 9: 
1,   2,   3,   4,   5,   6
2009; 8: 
1,   2,   3,   4,   5,   6
2008; 7: 
1,   2,   3,   4
2007; 6: 
1,   2,   3,   4
2006; 5: 
1,   2
2005; 4: 
1,   2
2004; 3: 
1
2003; 2: 
1,   2
2002; 1: 
1,   2

News Updates